睾酮对低促性腺激素性性腺功能减退症患者FGF2、MRF4与肌肉生长抑制素的影响
结果显示HH患者FGF2与FGFR2表达显著低于正常对照,睾酮治疗后FGF2表达升高,MRF4与肌肉生长抑制素表达下降。
要点
- HH患者骨骼肌FGF2与FGFR2表达较性腺功能正常男性显著降低。
- 睾酮治疗22周后FGF2表达升高,MRF4与肌肉生长抑制素表达下降。
- 睾酮可能通过调控上述因子促进肌肉生长。
核心结论
- 睾酮是骨骼肌FGF2、MRF4和肌肉生长抑制素表达的重要调节因子。
- 这些效应可能有助于解释睾酮治疗后肌肉量的增加。
研究设计与样本
- 既往完成的睾酮替代试验的二次分析。
- 基线比较22例HH男性与20例性腺功能正常男性。
- 治疗前后行股四头肌活检并采集血样。
主要发现
- HH患者骨骼肌FGF2和FGFR2表达分别较性腺功能正常男性低57%和39%(P < 0.05)。
- 睾酮治疗22周后FGF2表达升高,MRF4和肌肉生长抑制素表达显著下降。
- FGFR2、肌细胞生成素和肌源性分化蛋白表达无变化。
- 睾酮治疗后血浆FGF2和IGF-1浓度升高。
临床怎么用
- 对HH合并2型糖尿病男性,睾酮替代可能通过上调FGF2、下调MRF4与肌肉生长抑制素促进肌肉生长。
- 监测睾酮治疗对肌肉相关因子及血浆FGF2、IGF-1的影响可作为评估肌肉效应的参考。
局限性
- 研究人群为合并2型糖尿病的HH男性,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Fibroblast growth factor (FGF)2 is an important stimulatory modulator of satellite cells in skeletal muscle. Satellite cells play a cardinal role in muscle growth and repair. OBJECTIVE: We evaluated whether skeletal muscle expression of FGF2 and muscle growth and differentiation factors are reduced in patients with hypogonadotropic hypogonadism (HH) and whether testosterone replacement therapy results in their restoration. DESIGN: This is a secondary analysis of a previously completed trial of testosterone replacement in men with type 2 diabetes and HH. SETTING: Clinical Research Center at a university. PATIENTS: Twenty-two men with HH and 20 eugonadal men were compared at baseline. INTERVENTIONS: Twelve men with HH were treated with intramuscular injections of 250 mg testosterone every 2 weeks for 22 weeks, and 10 men received placebo injections. Quadriceps muscle biopsies and blood samples were obtained before and after testosterone therapy. OUTCOME MEASURES AND RESULTS: The expression of FGF2 and FGF receptor (FGFR)2 in skeletal muscle of men with HH was significantly lower than that in eugonadal men by 57% and 39%, respectively (P < 0.05). After 22 weeks of testosterone, the expression of FGF2 increased, whereas that of myogenic regulatory factor (MRF)4 and myostatin decreased significantly. There was no change in expression of FGFR2, myogenin, or myogenic differentiation protein in the skeletal muscle. Plasma FGF2 and IGF-1 concentrations increased after testosterone therapy. CONCLUSIONS: These data show that testosterone is a major modulator of FGF2, MRF4, and myostatin expression in skeletal muscle. These effects may contribute to the increase in muscle mass after testosterone therapy.
引用
- Ghanim H, Dhindsa S, Batra M, et al. Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth. J Clin Endocrinol Metab. 2019. PMID: 30629183. doi:10.1210/jc.2018-01832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。